Boehringer bails out of virology R&D

Share this article:
Boehringer Ingelheim is getting out of virology and will shut down a Quebec research facility, eliminating 170 positions in the process.

Boehringer's Dr. Michael Pairet, SVP responsible for R&D, cast the move as part of an effort to refocus the firm's R&D portfolio on areas of unmet need.

“In virology, compared to other therapeutic areas in which Boehringer Ingelheim is conducting research, the demands for medical innovation are shifting significantly due to the availability of new medications and also the emphasisi on prevention through vaccination, a field in which Boehringer Ingelheim is not active. With the renewed focus on the diseases of high unmet medical need, and considering the scientific possibilities, we decided to conclude virology research at Boehringer Ingelheim,” he said.

Boehringer's virology franchise included pipeline candidates for hepatitis C and HIV/AIDS. The company said it will continue work on its HCV portfolio, including faldaprevir, an investigational oral HCV NS3/4A protease inhibitor in Phase III; BI207127, a NS5B RNA-dependent polymerase inhbitor in Phase II trials as part of an interferon-free regimen; and the company's clinical trial program HCVerso. Marketed products in that area include antiretrovirals Viramune and Aptivus.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...